Screener
Revvity RVTY Life Sciences — Acquisitions, earn outs and other
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Revvity in its filing.
Tagged under the XBRL concept revv:GoodwillAcquisitionEarnOutsAndOtherAdjustments.
The source filing: Revvity’s 10-K, filed February 24, 2026.
- Filed
- Feb 24, 2026, 4:10 PM EST
- Fiscal year
- FY2025
- Accession
- 0000031791-26-000012
| Line item | Life Sciences | Diagnostics | Consolidated |
|---|---|---|---|
| Balance at December 31, 2023 | $4,587,938 | $1,945,612 | $6,533,550 |
| Foreign currency translation | (46,471) | (23,460) | (69,931) |
| Balance at December 29, 2024 | 4,541,467 | 1,922,152 | 6,463,619 |
| Foreign currency translation | 105,495 | 44,379 | 149,874 |
| Other | 98,000 | (98,000) | — |
| Balance at December 28, 2025 | $4,744,962 | $1,868,531 | $6,613,493 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Revvity's life sciences — acquisitions, earn outs and other?
- Revvity (RVTY) reported life sciences — acquisitions, earn outs and other of $24.5M in Q4 2025.
- What does life sciences — acquisitions, earn outs and other mean?
- This represents costs associated with integrating acquired businesses, including contingent consideration payments and other transaction-related expenses within the Life Sciences segment. It highlights the ongoing financial commitment required to realize the value of inorganic growth strategies.
Ask your AI about Revvity's life sciences — acquisitions, earn outs and other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude